These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 39110432)
41. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience. Martínez-Doménech A; Zaragoza-Ninet V; Esteve-Martínez A; García-Rabasco A; Sánchez-Carazo JL; Pérez-Ferriols A Actas Dermosifiliogr; 2024 Feb; 115(2):150-158. PubMed ID: 37858860 [TBL] [Abstract][Full Text] [Related]
42. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience. Martínez-Doménech A; Zaragoza-Ninet V; Esteve-Martínez A; García-Rabasco A; Sánchez-Carazo JL; Pérez-Ferriols A Actas Dermosifiliogr; 2024 Feb; 115(2):T150-T158. PubMed ID: 38048951 [TBL] [Abstract][Full Text] [Related]
43. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914 [TBL] [Abstract][Full Text] [Related]
44. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study. Hosseini-Ashrafi M; Clayton TH; Herring M; Herety N; Arkwright PD Clin Exp Dermatol; 2024 May; 49(6):578-583. PubMed ID: 38189448 [TBL] [Abstract][Full Text] [Related]
45. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972 [TBL] [Abstract][Full Text] [Related]
46. Dupilumab in Elderly Patients With Severe Atopic Dermatitis. Russo F; Milanesi N; Cartocci A; Bruzziches F; Tronconi G; Lazzeri L; D'erme AM; Bagnoni G; Gola M; Cinotti E; Rubegni P; Flori ML Dermatitis; 2021 Oct; 32(1S):S24-S27. PubMed ID: 33332865 [TBL] [Abstract][Full Text] [Related]
47. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study. Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676 [TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361 [TBL] [Abstract][Full Text] [Related]
50. Effect of dupilumab on sleep disturbances in adult patients with severe atopic dermatitis. Milanesi N; Gola M; Cartocci A; Tronconi G; Bruzziches F; Flori ML; Rubegni P; Russo F Ital J Dermatol Venerol; 2022 Apr; 157(2):142-145. PubMed ID: 34282867 [TBL] [Abstract][Full Text] [Related]
51. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice. Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732 [TBL] [Abstract][Full Text] [Related]
52. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. de Wijs LEM; Bosma AL; Erler NS; Hollestein LM; Gerbens LAA; Middelkamp-Hup MA; Kunkeler ACM; Nijsten TEC; Spuls PI; Hijnen DJ Br J Dermatol; 2020 Feb; 182(2):418-426. PubMed ID: 31145810 [TBL] [Abstract][Full Text] [Related]
53. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203 [TBL] [Abstract][Full Text] [Related]
54. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24. Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087 [TBL] [Abstract][Full Text] [Related]
56. Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study. Berna-Rico E; Fiz-Benito E; Busto-Leis JM; Servera-Negre G; de Lucas-Laguna R; Feito-Rodriguez M Dermatology; 2024; 240(2):337-342. PubMed ID: 38035567 [TBL] [Abstract][Full Text] [Related]
57. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499 [TBL] [Abstract][Full Text] [Related]
58. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials. Alexis AF; Rendon M; Silverberg JI; Pariser DM; Lockshin B; Griffiths CE; Weisman J; Wollenberg A; Chen Z; Davis JD; Li M; Eckert L; Gadkari A; Shumel B; Rossi AB; Graham NM; Ardeleanu M J Drugs Dermatol; 2019 Aug; 18(8):804-813. PubMed ID: 31424712 [TBL] [Abstract][Full Text] [Related]
59. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. Olesen CM; Holm JG; Nørreslet LB; Serup JV; Thomsen SF; Agner T J Eur Acad Dermatol Venereol; 2019 Aug; 33(8):1562-1568. PubMed ID: 30959559 [TBL] [Abstract][Full Text] [Related]
60. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. Drucker AM; Morra DE; Prieto-Merino D; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C JAMA Dermatol; 2022 May; 158(5):523-532. PubMed ID: 35293977 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]